These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28954127)

  • 1. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
    Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
    JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
    [No Abstract]   [Full Text] [Related]  

  • 5. Painful Rashes on the Palms and Soles.
    Bhullar M; Bhullar A; Arachchi NJ
    Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
    [No Abstract]   [Full Text] [Related]  

  • 6. Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
    Negri FV; Porta C
    J Clin Oncol; 2015 Oct; 33(28):3219-20. PubMed ID: 26215963
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 9. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 12. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
    Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 14. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 15. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
    Borgia F; Saitta C; Vaccaro M; Franzè MS; Lentini M; Cannavò SP
    Int J Immunopathol Pharmacol; 2017 Sep; 30(3):327-331. PubMed ID: 28825507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
    Tajiri K; Nakajima T; Kawai K; Minemura M; Sugiyama T
    Intern Med; 2015; 54(6):597-600. PubMed ID: 25786448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
    Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
    Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
    [No Abstract]   [Full Text] [Related]  

  • 18. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
    Ochi M; Kamoshida T; Ohkawara A; Ohkawara H; Kakinoki N; Hirai S; Yanaka A
    World J Gastroenterol; 2018 Jul; 24(28):3155-3162. PubMed ID: 30065561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Xu L; Wang B; Ding W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.